Pharmaceutical Business review - Page 619 of 5224 -

Oncology

November 4, 2024

NEOGAP and NorthX Biologics partner for cancer cell therapy production

NEOGAP Therapeutics has entered into a partnership with NorthX Biologics, a Swedish contract development and manufacturing organisation (CDMO), to enhance the manufacturing strategies for its personalised cancer cell therapy.

Continue

NEOGAP Therapeutics is currently developing a cell therapy known as personalised tumour trained lymphocytes. Credit: NEOGAP Therapeutics.

Deals

Whitepapers

Drug Discovery

Research & Development

Ring Therapeutics signs partnerships to advance R&D in biomedical sciences

insitro collaborates with Lilly on metabolic disease treatments

Clinical Trials

Patient Enrollment

US FDA approves Avacta Group’s IND application for AVA6000

AM-Pharma enrols first patients in Covid-19 phase III trial

Regulation

Drug Filing

Neuvivo files NDA seeking FDA approval for ALS treatment

FDA grants priority review for AstraZeneca’s Calquence sNDA

Production & Sales

Manufacturing

ENCell and Lucy Biotech forge alliance for mesenchymal stem cell therapy

Merck introduces single-use reactor to accelerate ADC manufacturing

Packaging & Supply Chain

Packaging

Gerresheimer

PCI Pharma announces bottling line expansion at Rockford site

Suppliers

No data found

NEOGAP and NorthX Biologics partner for cancer cell therapy production

Ring Therapeutics signs partnerships to advance R&D in biomedical sciences

Shanghai Henlius Biotech, Organon announce FDA acceptance of BLA for HLX14

Bavarian Nordic secures $156.8m US vaccine deal

Boehringer Ingelheim receives EC conditional marketing approval for spesolimab

Marinus Pharmaceuticals signs collaboration agreement with Tenacia Biotechnology

Harbour BioMed, Moderna partner on immunotherapies development

Merck enhances ophthalmology portfolio with EyeBio acquisition

Biocon signs licensing and supply deal for diabetes drug in Brazil

Q32 Bio concludes merger deal with Homology Medicines

Zuellig Pharma acquires Cialis and Alimta brands from Lilly

Popular

Pharmaceutical Business review is using cookies